Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Advanced Search Go
Free Newsletter Sign Up

Exelixis Says FDA Approves Cabometyx in Combination With Opdivo

Jan. 22, 2021, 6:16 PM

Exelixis, Inc. received FDA approval of CABOMETYX for patients with advanced renal cell carcinoma (RCC) as a first-line treatment in combination with OPDIVO.

  • Approval is based on results from CheckMate -9ER trial
  • Exelixis shares currently up about 2.4%

To view the source of this information click here

To contact the reporter on this story:
Cara Moffat in Los Angeles at

To contact the editor responsible for this story:
Lauren Berry at

© 2021 Bloomberg L.P. All rights reserved. Used with permission.